SUPREME-SECURE is a Unitaid-funded program working to strengthen sustainable access to quality-assured diagnostics and treatments for preeclampsia, eclampsia, and maternal anemia in sub-Saharan Africa. CHAI is leading this initiative in partnership with Concept Foundation, Aurum Institute, Burnet Institute, and WACI Health.
As part of the program’s market access work, Concept Foundation is now accepting proposals from manufacturers of low-dose aspirin and magnesium sulphate – inviting partners to help improve the quality, availability, and affordability of two essential maternal health medicines.
Low-dose aspirin (75 mg oral tablets)
Low-dose aspirin is the WHO-recommended intervention for the prevention of preeclampsia in high-risk pregnancies. Concept Foundation is seeking manufacturers capable of supplying quality-assured 75 mg tablets, with support available for product development, regulatory submissions, and registration and supply in target markets.
View RFP on Concept Foundation’s website
Magnesium sulphate (0.5 g/mL injection)
Magnesium sulphate is the WHO-recommended treatment for the prevention and treatment of eclampsia. Concept Foundation is seeking manufacturers capable of supplying quality-assured injectable MgSO4, with support available for regulatory submissions, WHO prequalification, and registration and supply in target markets.
View RFP on Concept Foundation’s website
Key dates
- Information session for aspirin: May 12, 2026
- Information session for magnesium sulphate: May 13, 2026
- Proposal submission deadline (both): June 5, 2026
Target countries include Ghana, Kenya, Malawi, Senegal, and Tanzania, with potential for broader low- and middle-income country reach. Selected manufacturers may receive technical assistance and/or financial support to accelerate development, approval, and supply.
Questions? Contact Concept Foundation at rfp_tx@conceptfoundation.org.
